Matt Bursavich

Matt Bursavich, PhD is Vice President, Head of Chemical Sciences at Morphic Therapeutic. He joined the company at an early stage as a drug hunter to help build the MInT platform and lead the α4β7 program. Prior to Morphic Matt was most recently at Forum Pharmaceuticals, where he focused on designing therapeutics for brain diseases. At Forum, he led the gamma secretase modulator team that advanced compounds into development for familial Alzheimer’s Disease.

Matt began his medicinal chemistry career at Wyeth where he led and contributed to programs in multiple therapeutic indications, including oncology, inflammation, and neuroscience. He is an author of over 80 publications and patents. Matt obtained a BSc degree in chemistry from Louisiana State University and a PhD in organic chemistry from the University of Wisconsin.